Development and Validated Stability of RP-HPLC Method for Assay of Agomelatine Drug in Tablet Dosage Form

Rashmi Darshan Wani, Suvarna Manoj Bhadane, Smita Nitin Takarkhede, Bhagyashree Kunal Pawar, Balmukund Rathi, Shriram Bairagi, Ujwala Ghogare, Ajay Kharche, Rupali Yevale, Roshani Chaudhari

Received: 13 March 2019 • Revised: 17 April 2019 • Accepted: 23 April 2019

Abstract: A simple, efficient, and precise stability indicating RP-HPLC method has been developed and validated to measure Agomelatine at wavelength (230 nm) in order to assay. Agomelatine is used to treat Depression. Methanol was used as a solvent with λ max of drug was found to be 230 nm. The samples were eluted in an isocratic method using Water symmetry (C18, 5um, 4.6nm×250mm) with a mobile phase consisting of pH 5.0 Buffer Dipotassium Hydrogen Phosphate: ACN (50:50) using as diluents through ambient temperature delivered at a flow rate 1.2mL/min. Linearity was observed in the range of 20-120µg/ml with a regression coefficient of 0.99. Stability of analytical solution was carried out at different time interval 0, 24, 36 and 48hr. The stress testing of the drugs was carried out under acidic, alkaline, photo-stability, neutral, oxidation and dry heat conditions. The method was quantitatively evaluated in terms of accuracy (recovery), linearity, precision, selectivity and robustness in accordance with standard ICH validation guidelines. The method is simple and suitable for analyzing Agomelatine in bulk and in pharmaceutical formulations.

Keywords: HPLC; Agomelatine, Validation, Stability, Accuracy .

Abbreviations: UV Detector: Ultraviolet Detector; RSD: Relative Standard Deviation; HPLC: High Performance Liquid Chromatography; ICH: International Conference on Harmonization; GABA: Gamma Amino Butyric Acid; SD: Standard Deviation; PDA: Photodiode array; LOD: Limit of Detection; LOQ: Limit of Qualification; DNA: Deoxyribonucleic acid; RNA: Ribonucleic Acid; HIV: Human Immunodeficiency Virus; LC: Liquid Chromatography; LC-MS: Liquid Chromatography-Mass Spectroscopy; USP: United States Pharmacopeia; Rt: Retention time; RT: Room Temperature

INTRODUCTION

In a quest to make available drugs for ever increasing diseases, disorders and ailments, new drugs, drug combinations and formulations are being introduced on regular interval. Due to this, analytical chemists are facing challenges for the scope of developing and validating a method to ensure a suitable strategy for a particular analyze which is more specific, accurate and precise.

Rashmi Darshan Wani, Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, India. Suvarna Manoj Bhadane, Quality Assurance, Ideal College of Pharmacy and Research, India. Smita Nitin Takarkhede, Pharmaceutics, Ideal College of Pharmacy and Research, India.

Bhagyashree Kunal Pawar, Quality Assurance, Munoot College of Science and Technology, India. Balmukund Rathi, Ideal College, India.

Shriram Bairagi, Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, India. Ujwala Ghogare, Pharmacognosy, Ideal College of Pharmacy and Research, India.

Ajay Kharche, Pharmaceutical Chemistry, Ideal College of Pharmacy and Research, India. Rupali Yevale, Pharmaceutical Chemistry, Kokan Gyanpeeth College of Pharmacy, India.

Roshani Chaudhari, Pharmacognosy, Ideal College of Pharmacy, India.

The main aim of this work was "to design, develop and validate a stable and highly effective analytical assay method for the estimation of Anti-depressant drug Agomelatine in tablet dosage form.^[1] ^[2] ^[3] ^[4]

Agomelatine is a potent agonist of melatonin (MT_1 and MT_2) receptors with HT_2C antagonist properties. It is also a 5- HT_2B antagonist. Agomelatine does not interact with adenosine, adrenergic, dopamine, GABA, muscarinic, nicotinic, histamine, excitatory amino acid, and benzodiazepine and sigma receptors, not with sodium, potassium or calcium channels. Through its 5- HT_2C antagonist effect, Agomelatine increases dopamine and nor-adrenaline release specifically in the prefrontal cortex. ^[5] ^[6] ^[7]




Fig. No.1: Chemical structure of Agomelatine ^[9] Table No.1: Properties of Agomelatine

IUPAC Name	N-[2-(7-methoxynaphthalen-1-yl) ethyl] Acetamide			
Chemical Formula	C15H17NO2			
Molecular Mass	243.301			
Category	Anti-Depressant			
pKa value	15.94			
Potency of drug	99.09%			
Physical State	White or White alike crystal powder			
Melting Point	108 °C			
Solubility	Organic solvents such as Ethanol, DMSO and Dimethyl Formamide			
Table No. 2: List of chemicals				

Chemicals	Manufacturer
Drug API	Watson (Mumbai)
Methanol	Rankem
Acetonitrile	Rankem
Di-potassium hydrogen phosphate	Merck
Acetic acid	Merck
Hydrochloric acid	Qualigens Fine Chemicals
MilliQ Water	Millipore Water

Table No.3: List of equipment/instruments

Name	Brand Name
HPLC	Waters HPLC 2489
Software	Empower
UV-visible Spectrophotometer	Shimadzu- 2010 A
pH Meter	Thermo Orion 3 Star
Electronic Balance	Mettler Toledo
Sonicator	Citizen CD-4820

Materials and Methods [10] [11] [12] [13] [14] [15] [16]

1. Materials

Pure sample as well as capsule dosage form of Agomelatine was obtained from Watson Pharmaceutical Pvt Ltd Mumbai. All the chemicals were used of analytical grade. The Methanol HPLC Grade methanol was used as a solvent throughout the studies.

2. Determination Of λ max

Preparation of stock solution

Weighed accurately 10mg of drug and was dissolved in 10 ml of Methanol to give concentration of 1mg/ml (Stock Solution-A).

Preparation of Standard Stock solution

1ml of Solution (A) was diluted with methanol in 100ml volumetric flask to give concentration of $10\mu g/ml$ (Standard Stock Solution B) and series of 5-35 $\mu g/ml$ of concentrations were prepared. Agomelatine showed absorbance maxima at 284nm.




Fig.No.2: UV spectrum of Agomelatine USP **Preparation of Standard Solution**

Accurately weighed 50 mg of Agomelatine standard, 70 ml of diluent was added and sonicated. The volume was made up to 100 ml with diluent. Further 5.0 ml of this solution was diluted to 50 ml with diluent and was mixed well.

Preparation of Sample stock Solution

Accurately weighed 5 intact tablets were transferred to a 250 ml volumetric flask; 50 ml of purified water was added and sonicated to disintegrate tablets completely, 150 ml of methanol added and sonicated for 30 minutes with intermittent swirling, cooled and diluted up to mark with Methanol and mixed well and centrifuged. The supernatant solution was filtered through 0.45 μ Nylon MDI filter discarding first 10 ml of the filtrate. Further 5 ml of the remaining filtrate was diluted to 50 ml with diluent and was mixed well.

able No.4: Optimization of chromatographic parameters				
HPLC	Waters HPLC 2489			
Mobile Phase	Buffer : Acetonitrile (50:50)			
Column	Water Symmetry C18,5um,4.6nm×250mm			
Diluents	Mobile Phase			
Flow rate	1.2 ml /min			
Detector	230 nm			
Column Temperature	35∘ C			
Injection Volume	20 µl			
Run time	12 min			

Table No.4: Optimization of chromatographic parameters

Assay Method [18]

Preparation of buffer: It was prepared by dissolving 1.74 g of di-potassium hydrogen phosphate into 1000 ml milli-Q water, sonicated and mixed; pH was adjusted to 5.0 +- 0.05 with glacial acetic acid solution. Solution was filtered through 0.45µm Nylon membrane filter paper.

Preparation of Mobile phase: Mix buffer pH 5.0+-0.05 and acetonitrile in the ratio 40:60 v/v and sonicate to degas.

Preparation of Diluent: Prepare a mixture of Methanol and Water in the proportion of 80:20

Preparation of Standard Solution

5 ml of stock solution pipette out and diluted up to 50 ml with mobile phase in volumetric flask.

Analytical method and Method Validation [19] [20]

Specificity Sample Solution

Retention time of peak in standard and sample solution was found to be 4.509 and 4.507 min.




Fig. 3: Specificity of Sample Solution Fig. 4: Specificity of Standard Solution Chromatogram Chromatogram

Sr No.	Sample Name	RT	Area
1	Agomelatine Standard	4.507	407530
2	Agomelatine Sample	4.509	407712
3	Placebo	-	-
4	Blank	-	-
	Average	40	07548
	SD	704.98	
	%RSD	0.17%	

Table No.5: Specificity of Agomelatine

Linearity and Range

Linearity was evaluated in the range of 20% to 120% of the working concentration level. Correlation of coefficient of Agomelatin was found to be 0.99.




Table No.6: Linearity of Agomelatine Accuracy (Recovery)

Sr. No.	Conc. (µg/ml)	Mean Peak Area
1	20	2538795
2	40	5295862
3	60	8588283
4	80	10266161
5	100	13316882
6	120	16117544

Placebo of capsule was spiked at three different levels: 50%, 100% and 150% of the label claim in triplicate. Each of the sample preparation was injected in triplicate and the average area count was taken for calculation.

Level	Amount added in mg	Amount Recovered	% Recovery	Average % Recovery
	24.775	24.76	99.95	99.67%
50%	24.775	24.61	99.32	
	24.775	24.74	99.86	
	49.550	49.61	100.12	99.9%
100%	49.550	49.56	100.01	
	49.550	49.34	99.57	
	74.325	74.29	99.96	99.89%
150%	74.325	74.30	99.97	
	74.325	74.18	99.80	

Table No.7: Data sheet of Recovery

Sr. No.	Level	% Recovery	SD	RSD
1	50	99.67	0.3407	0.34
2	100	99.9	0.2910	0.29
3	150	99.89	0.0953	0.095

Table No.8: Statistical analysis for recovery data

Mean recovery was found to be 100.33% and RSD was 0.09%.

Limit of Detection (LOD) and Limit of Quantitation (LOQ)

LOD: It is the smallest amount of concentration of analyte in the sample than can detect which will be reliably distinguished by zero.

LOQ: It is the smallest amount of analyte in the sample which can be distinguished with suitable precision and accuracy.

Table No.9: LOD and LOQ				
Sample	Parameter			
	LOD (µg/ml)	LOQ (µg/ml)		
Agomelatine (μg/ml) 2.830 9.434				
Precision [21] [22]				

1. System Precision

System precision was evaluated by measuring of absorbance of drug from six replicate injection of standard preparation (10 ug/ml) were injected into UV and %RSD was calculated.

Table No.10: System Precision						
Injection No	1	1 2 3 4 5 6				
Area	407645	40921	409771	407413	409955	409982
Mean		408781.2				
SD	1221.87					
%RSD	0.298					

The RSD of system precision was found to be 0.298%. Therefore, the UV method for the determination of X capsule was precise.

2. Method precision

System precision was evaluated by measuring of absorbance of drug from six replicate injection of standard preparation ($10 \mu g/ml$) were injected into UV and %RSD was calculated.

Table N	Table No.11: Method Precision				
Sample	Mean peak area	% assay			
1	407142	99.15			
2	407256	98.95			
3	407622	98.91			
4	407401	98.94			
5	407340	99.14			
6	407412	99.18			
	Mean	99.04			
	% RSD	0.13			

The RSD of method precision was 0.2%. Therefore, the HPLC method for the determination of Agomelatin was reproducible.

3. Intermediate precision (Ruggedness)

Six standard solutions and six sample solutions of the same lot of the capsule was made by a different analyst, using same column on a different day and injected in duplicate into different UV system. The mean and percent RSD values for area were calculated.

Sample	Analyst-1 % Label claim	Analyst-2 % Label claim	
1	98.4	98.5	
2	95.7	96.6	
3	98.5	98.4	
4	96.6	95.7	
5	96.4	95.9	
6	95.8	96.4	
Mean	96.90	96.91	
%RSD	1.28	1.28	
Overall mean	96.9		
Overall %RSD	1.17		

Table No.12: Intermediate precision

The RSD of Ruggedness was found to be 1.17%. Therefore, the HPLC method for the determination of Agomelatin tablet was rugged.

Table No.13: System Suitability Parameters			
Parameters	Drug X		
Tailing factor (T)	0.99		
Number of Theoretical plate (n)	34379		
Retention time (RT)	4.159		
% RSD	0.77		
S/N ratio	23		
	ParametersTailing factor (T)Number of Theoretical plate (n)Retention time (RT)% RSD		

System Suitability

Stability of Analytical Solution^[23]

Stability of sample solution was determined by injecting (in triplicate) tablet sample solution at different time intervals.

Table No.14: Stability of Analytical solutions at room temperature


Sr. No	Name	% Content 0 Hr	% Content 24 Hr	% Content 36 Hr	% Content 48 Hr	
1	Standard Solution	100.0	100.5	100.7	100.9	
2	Sample Solution	100.0	100.4	100.7	100.9	

Forced Degradation Studies ^{[24] [25]}

Accurately weighed quantity of tablet powder equivalent to about 30 mg of Agomelatin was transferred separately to six different 50.0 ml volumetric flask, (flask no. 1, 2, 3, 4, 5 and 6). To flask no. 1, 2 and 3, added 3.0 ml methanol as co-solvent followed by addition of 5.0 ml 5 M HCl, 0.1 M NaOH and 1 % H_2O_2 to flask no.1, 2, and 3, respectively.

For neutral hydrolysis, 5.0 ml of water was added to flask no.4. The content of flask no. 1 were heated on water bath at 80°C for 6 hr. whereas content of flask no. 2, 3 and 4 were heated on water bath at 80°C for 2 hr, Flask no. 5 containing tablet powder was kept in hot air oven at

80°C for 24 hr to study the effect of heat on tablet sample (heat degradation). Flask no.6 containing tablet power was exposed to UV-radiations for 24 hr to study the effect of light on tablet sample (photo degradation). After stipulated time interval, the entire flasks were removed and cooled to room temperature. The samples were then treated and analyzed.







Fig.No.6: Acid Degradation of Sample






Fig.No.10: Peroxide Degradation of Sample Fig.No.11: Photo Degradation of Sample Table No.15: Forced Degradation Studies

	Tuble Holizof Toreed 2 ograduation Staales					
Sr. No	Stress Conditions	Temperature and Time	% Assay of Active substance	Retention time of Degraded Produc	% Degradation	
1	Acid (5 M HCl)	800C for 6 hr	73.43	2.66, 3.37	27%	
2	Alkali (0.1 M NaOH)	800C for 2 hr	90.69	2.58	10%	
3	Oxide (1 % H2O2)	800C for 2 hr	97.91	-	3%	
4	Neutral	800C for 2 hr	84.31	2.65	16%	
5	Heat	800C for 24 hr	99.39	-	1%	
6	Photo degradation	24 Hr	99.07	-	1%	

RESULT

Forced degradation studies for Agomelatine shows:

1) Acidic Degradation (5M HCl) at 80°C for 6 hr Drug shows degradation 27%

2) Alkaline Degradation (0.1 M NaOH) at 80°C for 2 hr Drug shows degradation 10%

3) Neutral Degradation at 80°C for 2 hr Drug shows degradation 16%.

So it can be concluded that the parameters Accuracy, Precision, Specificity, LOD and LOQ are according to the standard limits. And the stress testing of the drugs was carried out under acidic, alkaline, photo-stability and dry heat conditions. Agomelatin was susceptible to acid and alkaline degradation than thermal and photo degradation conditions.

The method developed for quantitative determination of Agomelatin is rapid, precise, accurate and selective. The developed method can be conveniently used for the assay determination of Agomelatin in bulk drugs and pharmaceutical dosage form.

CONCLUSION

Under the conditions described the method is found to be specific, rugged, robust, accurate and linear. The method is suitable for the assay of Agomelatine.

Sr. No.	Validation Parameter	Acceptance Criteria	Result	
1	Specificity		Pass	
1.1	Identification	Results should be comparable with respect to retention time.	Pass	
1.2	Placebo Interference	Blank and Placebo should not show any peak at the retention time of drug x Peak.	Pass(No interference)	
2	Linearity & Range	Correlation Coefficient should not be less than 0.999	Pass (1.0)	
3	Accuracy (Recovery)	Mean recovery should be in the range of 98.0% to 102%. The RSD should not be more than 2.0%.	Pass	
4	Precision			
4.1	System Precision	RSD should not be more than 2.0%.	Pass	
4.2	Method Precision	RSD should not be more than 2.0%.	Pass	
5	Ruggedness	RSD should not be more than 2.0%.	Pass	
6	Robustness			
6.1	Change in column Temperature (+5°C)	RSD should not be more than 2.0%.	Pass	
6.2	Change in flow rate (± 0.1mL/min)	RSD should not be more than 2.0%.	Pass	
6.3	Change in pH (± 0.2)	RSD should not be more than 2.0%.	Pass	

Table No.16: Validation report of the assay of Drug in capsule dosage form by UV

REFERENCES

- ^[1] Chung CC, Herman L, Lee YC, Xue-Ming Zang, Analytical Method Validation and Instrument Performance Verification. A John Wiley & Sons, Inc., Publication, 2004; pp. 11-12
- ^[2] Willard HH, Merritt, Jr. L.L., Dean, JA, Settle Jr. FA. 7th ed, Instrumental Methods of Analysis, CBS Publishers and Distributors, Delhi, 2001; pp. 1.
- ^[3] Mendham J, Denney RC, Barnes JD, Thomas M, Vogel's Textbook of Quantitative Analysis. Pearson Education, Singapore, 2003; pp. 8-9.
- ^[4] Skoog A, Holler FJ, Timothy A, Nieman NW, Principle of Instrumental Analysis, 5th ed., Eastern Press, Banglore, 2004; pp.1-2:678-688, 695-696.
- ^[5] Sethi P D. Quantitative Analysis of Drugs in Pharmaceutical Formulations. New Delhi, CBS Publishers and Distributors, p. 52-53, 2005.
- ^[6] Sharma B K. Instrumental Methods of Chemical Analysis, Meerut, Goel Publishing House, p.3-5, 10, 2002
- ^[7] Munson J W. Pharmaceutical Analysis. Modern Methods, Part-B, Mumbai, International Medical Book Distributors, p. 51-54, 2001.
- [8] Christian G D. Analytical Chemistry. 6th ed, Singapore, John Wiley and Sons (Asia) Pvt. Ltd, p.623-627, 2003.
- ^[9] http://www.drugbank.ca/drugs/.Retrived
- ^[10] David H. Modern Analytical Chemistry, McGraw-Hill Companies, Tom Kupiec; Quality Control Analytical Method-High Performance Liquid Chromatography, Okhlalamba, Analytical Research Laboratory, p. 225
- ^[11] Snyder L R, Glajch J L, Kirkland J J. Practical HPLC Method Development. 2nded, USA, John Wiley & Sons, Inc., Wiley-Inter-science Publication, p. 165-170, 1997.
- ^[12] Berry R I, Nash A. R., Pharmaceutical Process Validation; Analytical method validation. New work, Marcel Dekker Inc. 57, p. 411-28, 1993
- ^[13] Balamurali K K, Mahendra K, Syama Sunadar B A. A validated reverse phase HPLC method for the simultaneous estimation of Drug X and Drug Y in pharmaceutical dosage forms. *DerPharmaChemica* 3(1), 2011.
- ^[14] Ahuja S, Scypinski S. Handbook of Modern Pharmaceutical Analysis. Academic Press, An Imprint of Elsevier, p.99, 2005.
- ^[15] Wani R, Madhavi A, Gaikwad B, Development and Validation of RP-HPLC Method for Assay of Agomelatine Drug in Tablet Dosage Form, International JETIR, p. 55 -64, Vol.6, Issue 2, 2019, ISSN: 2349-5162
- ^[16] Venisetty, Meghana M, Thota Sridhar, Development and Validation of Stability-Indicating RP-HPLC Method for the Estimation of Agomelatine in API, Research Journal of Pharmaceutical, Biological and Chemical Sciences, p.621-628, Vol.5, Issue 1, 2014
- ^[17] N. Venkata Ratnam, D. Gowri Sankar, P. Sindhu and T. Teja, Development and Validation of UV Spectrophotometric Method for Estimation of Agomelatine in Bulk and Pharmaceutical Dosage Form, Der Pharmacia Lettre, p.41-46, Vol.8, Issue 20, 2016.
- ^[18] El-Shaheny RN, Evaluation of agomelatine stability under different stress conditions using an HPLC method with fluorescence detection: application to the analysis of tablets and human plasma, Pubmed, Vol 29, Issue 7, p. 920-8, 2014.
- ^[19] Mukthinuthalapati M, Novel stability indicating RP-HPLC method for the determination of Agomelatine A novel antidepressant, Vol. 8, Issue 3, 2015, p.502-508
- ^[20] Vineela P, Pavani B, Ajitha A, Uma Maheshwara Rao.V, Analytical method development and validation and stability studies of the estimation of agomelatine in tablet dosage form by RP-HPLC, Vol 4, Issue 6, 2014, p. 348-352
- [21] Georgios N Rallis1, Petros Petrikis and Vassiliki A Boumba, Development and Validation of an UHPLC-UV method for the Determination of Agomelatine in Human Plasma and Serum Suitable for Routine Clinical Analysis, Annals of Chromatography and Separation Techniques, Vol.2, Issue 2, p. 1020, 2016
- ^[22] Buchi N Nalluri, Development and validation of RP-HPLC method for the estimation of agomelatine in bulk drug and pharmaceutical dosage forms, Research Gate, 2013

- ^[23] Katerina Plachka, Development, validation and comparison of UHPSFC and UHPLC methods for the determination of agomelatine, Elsevier, Vol.125, 2016, p. 376-384
- ^[24] ICH: Q2(R1) Text on Validation of Analytical Procedures , November 2005
- [25] ICH: Q2 (B) Validation of Analytical Procedures-Methodology, November 1996 Inc.2000, pp. 582-583.